AEB071 is an investigational drug that works by blocking an enzyme called protein kinase C (PKC). PKC is important for the growth of uveal melanoma (a cancer of the eye). MEK162 is an investigational drug that inhibits a protein called MEK1/2, which drives cancer growth. It has been shown to be active in some patients with melanoma of the skin, but has not yet been assessed in patients with uveal melanoma. Both AEB071 and MEK162 are taken orally (by mouth).
In this study, researchers want to find the highest doses of AEB071 and MEK162 that can be given when both drugs are used together in patients with uveal melanoma that has spread (metastasized) to other parts of the body. There are very few existing treatments that have been found to slow the growth of metastatic uveal melanoma.